Metabolic switches like increased oxidative phosphorylation are common themes in resistance to cancer therapy.

“when we look at what drives resistance to both targeted therapy so those molecules I referred to before these you know surface receptor and downstream molecules that have been successful and extend people's um lives with cancer and imun therapy and we and we look at common themes in terms of resistance this metabolic switch like using oxidative phosphorilation when they weren't using it before like that's a very common theme in what we call the persister cell population um in in both therapy types”